Many of the decisions made during the early days of building and compiling the manufacturing information for your IND submission will directly impact the future cGMP manufacturing operations and simply become foundational for the commercial viability of the developer’s pipeline of therapies.

Lonza’s Early Advantage program for IND success is designed to arm developers with the tools and expertise to anticipate these future outcomes and challenges, make the best possible educated decisions early-on, all while accelerating the journey to compiling your IND application and starting clinical trials.


Hadrien Piana, Director, Strategic Marketing, Cell and Gene Technologies

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center